Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma

Despite years of clinical progress which made Hodgkin lymphoma (HL) one of the most curable malignancies with conventional chemotherapy, refractoriness and recurrence may still affect up to 20–30% of patients. The revolution brought by the advent of immunotherapy in all kinds of neoplastic disorders...

Descripción completa

Detalles Bibliográficos
Autores principales: Hazane Leroyer, Esther, Ziegler, Caroline, Moulin, Charline, Campidelli, Arnaud, Jacquet, Caroline, Rubio, Marie Thérèse, Feugier, Pierre, Pagliuca, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656939/
https://www.ncbi.nlm.nih.gov/pubmed/36362802
http://dx.doi.org/10.3390/jcm11216574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656939/
https://www.ncbi.nlm.nih.gov/pubmed/36362802
http://dx.doi.org/10.3390/jcm11216574

Ejemplares similares